Other
ILD
0
Pipeline Programs↗
8
Active Trials↗
9
Companies Involved↗
ILD is an early-stage landscape with 0 programs across 9 companies. The most active players are Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Novartis, GSK.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
45
clinical trials
Completed29 · 64%
Unknown status5 · 11%
Recruiting4 · 9%
Terminated3 · 7%
Not yet recruiting2 · 4%
Active, not recruiting2 · 4%
Clinical Trials
Trial Activity
45 trials
A Study of SIPLIZUMAB in AILD and LT Patients
Recruiting·—·Phase 1·NCT06455280·8 enrolled
Romosozumab Use to Build Skeletal Integrity
Active, not recruiting·—·Phase 4·NCT05058976·184 enrolled
Sildosin as a Male Contraceptive Non Hormonal
Not yet recruiting·—·Phase 1·NCT07195097·200 enrolled
Rituxmab Versus IL-6 in Treating ILD
Completed·—·Phase 2/3·NCT05963048·60 enrolled
Motor Response to Sildenafil in PD
Completed·—·Phase 4·NCT01941732·8 enrolled
(Study: Vertex IIS) Does Ivacaftor Alter Wild Type CFTR-Open Probability In The Sweat Gland Secretory Coil?
Completed·—·N/A·NCT02310789·8 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)